Mme Docteur ELEONORE BERARD

Localisation des cabinets

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

• CABINET DU DR ELEONORE BERARD

  POLYCLINIQUE BORDEAUX NORD AQUITAINE — 33 RUE DOCTEUR FINLAY, 33300 Bordeaux

  Libéral
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

• CABINET DU DR ELEONORE BERARD

  HOPITAL SUBURBAIN DU BOUSCAT — 97 AVENUE GEORGES CLEMENCEAU, 33110 Le Bouscat

  Libéral
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

• HOPITAL SUBURBAIN DU BOUSCAT

  97 Avenue GEORGES CLEMENCEAU, 33491 Le Bouscat

  ☎ 0556424949Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Effects of tiludronate on bone loss in paraplegic patients

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 1995

  📚 68 citations🎯 RCR 3.01Top 16% NIH🩺 Clinique

  Lire l'abstract Crossref ↓

  Abstract Immobilization secondary to spinal cord injury is associated with a marked and rapid atrophy of trabecular bone (disuse osteoporosis). This is due to an early increase of osteoclastic bone resorption associated with a pronounced decreased osteoblastic bone formation. Bisphosphonates are antiosteoclastic compounds and they have been effective in preventing disuse osteoporosis. However, some of them also depress osteoblastic activity and may impair the mineralization process. Tiludronate was shown effective in reducing bone resorption in several metabolic bone diseases without inducing mineralization defects. Twenty paraplegic patients (6 females and 14 males) were randomly assigned to three groups: 6 patients entered the placebo group; 7 patients received tiludronate 200 mg/day; and 7 received 400 mg/day. Histomorphometric analysis was performed on transiliac bone biopsies before and after 3 months treatment An insignificant decrease of bone volume was observed in the placebo group and the 200 mg group. In patients receiving 400 mg/day, a slight increase was noted. Osteoid parameters changed nonsignificantly in three groups although the 400 mg group exhibited a slight tendency to decrease osteoid volume and thickness. Eroded surfaces increased in all groups. The number of osteoclasts (identified histochemically by TRAP staining) increased in the placebo group but decreased in groups receiving tiludronate. Tiludronate appears effective in reducing bone resorption without impairing bone formation in a manner that preserved bone mass and bone cell coupling.

• 2

  Determination of normal KOOS and WOMAC values in a healthy population

  Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2019

  📚 56 citations🎯 RCR 4.81Top 8% NIH
• 3

  Evaluation of the accuracy of patient-specific cutting blocks for total knee arthroplasty: a meta-analysis

  International orthopaedics · 2015

  📚 55 citations🎯 RCR 3.84Top 11% NIH

Publications scientifiques (20) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche